Comparison of A1C and Fasting Glucose Criteria to Diagnose Diabetes Among U.S. Adults

Carson, April P.; Reynolds, Kristi; Fonseca, Vivian; Muntner, Paul

doi:10.2337/dc09-1227

Cited by 163 publications

(144 citation statements)

References 7 publications

(11 reference statements)

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…Another analysis on 6890 adults without previouslydiagnosed diabetes from the 1999 -2006 NHANES study showed a reasonable consistency between HbA 1c and fasting glucose measurements for the purposes of diagnosing diabetes (k = 0.60; 95% CI 0.55, 0.64), although discrepancies were reported for non-Hispanic black patients [ 51 ].…”

Section: Hba 1c For Diagnosis and Monitoring Backgroundmentioning

confidence: 99%

Glycemic control in the clinical management of diabetic patients

Mosca

Lapolla

Gillery

2012

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

In clinical practice, glycemic control is generally assessed by measuring and interpreting glycated hemoglobin levels, however, this test should be run under standardized conditions. We focus here on the crucial steps to ensure IFCC standardized HbA 1c results, pointing out several residual weak points, mostly relating to the laboratory end-user (calibration, quality control materials, and EQAS). We also review the use of HbA 1c for diagnosing diabetes and the various indicators useful for assessing glucose variability because in some cases they seem to represent a patient ' s glucose profile more accurately than one-off HbA 1c assays. Finally, the potential utility of glycated albumin and the glycation gap, the costs involved and the laboratory management issues are briefly discussed.

show abstract

Section: Hba 1c For Diagnosis and Monitoring Backgroundmentioning

confidence: 99%

Glycemic control in the clinical management of diabetic patients

Mosca

Lapolla

Gillery

2012

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…This is because the current criteria adopted show a discrepancy between the proportion and profile of patients identified as having DM by the A1C, compared to the tests based on glycemia (45,46). In addition, the patients who present special conditions that interfere with A1C results should be screened for DM with alternative markers.…”

Section: Ga In the Diagnosis Of Dmmentioning

confidence: 99%

Glycated albumin: a potential biomarker in diabetes

Freitas

Ehlert

Camargo

2017

Arch. Endocrinol. Metab.

137

103

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a chronic and metabolic disease that presents a high global incidence. Glycated hemoglobin (A1C) is the reference test for long-term glucose monitoring, and it exhibits an association with diabetic chronic complications. However, A1C is not recommended in clinical situations which may interfere with the metabolism of hemoglobin, such as in hemolytic, secondary or iron deficiency anemia, hemoglobinopathies, pregnancy, and uremia. The glycated albumin (GA) is a test that reflects short-term glycemia and is not influenced by situations that falsely alter A1C levels. GA is the higher glycated portion of fructosamine. It is measured by a standardized enzymatic methodology, easy and fast to perform. These laboratory characteristics have ensured the highlight of GA in studies from the last decade, as a marker of monitoring and screening for DM, as well as a predictor of long-term outcomes of the disease. The aim of this review was to discuss the physiological and biochemistry characteristics of the GA, as well as its clinical utility in DM. Arch Endocrinol Metab.2017;61(3):296-304.

show abstract

“…98 using NHANES data, with cut-off levels of 6.5% for HbA 1c and 7.0 mmol/l for FPG. There was some disagreement between the tests, but 96% were not diagnosed as diabetic by both, and 1.8% were diagnosed as diabetic by both.…”

Section: Suggested Conclusionmentioning

confidence: 99%